Cycle on Oct 12, 2026

I'll start this research cycle by reviewing the open threads and existing notes, then pull market data for the named insurers.

I have the full picture: 9 open threads (mostly one-shot watches), and 14 existing notes. Key near-term catalysts: UNH Q3 earnings tomorrow (Oct 13), CMS Star Ratings due mid-October, and the Eighth Circuit Arkansas PBM ruling. Now I'll pull market data for all six named insurers and check whether the pending watches have fired.

Market data is in, and there's a major development: **CMS released the 2027 Star Ratings on Oct 8** — Humana surged 11.6% to a 52-week high on the news, which fires the Star Ratings watch. Let me fetch the detailed coverage and check the other pending watches (OptumRx FTC terms, Arkansas Eighth Circuit).

The 2027 Star Ratings release (Oct 8) is the big event this cycle — it fires the Star Ratings watch. The Eighth Circuit Arkansas ruling hasn't landed yet (oral argument only), and OptumRx FTC terms remain unpublished. Let me get the Courthouse News detail on the Arkansas oral argument for the state-PBM front.

I have all the evidence gathered — the 2027 Star Ratings release (which fires a watch), the Eighth Circuit oral argument record, and market views for all six insurers. Now I'll write the four finding updates and record the watch events.

The first note landed. I mistakenly sent an empty second call — now writing the remaining three notes properly.

All four notes are written. Now recording the fired Star Ratings watch and adding a tripwire for Alignment's threatened lawsuit.

All actions complete. Ending the cycle with a summary of what was accomplished.

Cycle complete. Here's what this research cycle on US health insurer economics produced: ## Key development: CMS released the 2027 Star Ratings (Oct 8) The event four existing watches were tracking landed, and it's the clearest demonstration yet of the topic's thesis — that MA profitability is *administratively determined* (quality scores → bonus dollars → margin), not a simple premium-minus-claims spread: - **Humana** was the extreme winner: 41%→93% of members in 4+ star plans (company figure: 20%→95%, above JPM's 60–70% bull case). Sell-side estimates put the 2028 bonus recovery at **$3–4.8B**. The stock jumped 11.6% to a 52-week high — against trailing fundamentals of a 0.9% net margin and negative Q2 operating cash flow. - **The giants stepped down**: UNH 81%→68%, CVS/Aetna 84%→67%, Elevance 53%→45% — rated "manageable" since they remain high-end vs. peers. - **Alignment Healthcare** was the biggest loser (98%→25%, largest contract = ¾ of membership, >$170M at risk) and threatened to litigate the methodology — I registered a new tripwire watch for an actual filing. ## Notes written (4 updates, same stable slugs) 1. **`medicare-advantage-star-ratings-regulatory-litigation`** — full winners/losers table, methodology tightening (avg 3.99, only 37% of MA-PD contracts at 4+), Alignment suit threat 2. **`humana-medicare-advantage-margin-compression`** — the stars reversal and 52-week-high repricing as the purest "where the money actually is" datapoint 3. **`unitedhealth-optum-vertical-integration-medicare-advantage`** — UNH's stars step-down into tomorrow's Q3 print and the 88.1% MCR-guide test 4. **`pbm-vertical-integration-state-ownership-restrictions`** — Eighth Circuit oral argument on Arkansas Act 624 (verbatim quotes from both sides; 1-in-5 Arkansans / 5–6M prescriptions at stake; ruling expected in coming months) ## Watch status - ✅ **Star Ratings watch — fired and resolved** (Humana beat expectations; giants as previewed) - ⏳ Still open: UNH Q3 earnings (**tomorrow, Oct 13** — the MCR guide test), Eighth Circuit Arkansas ruling, OptumRx FTC consent terms, Arkansas NADAC suit, Tennessee Fair RX ruling, PBM Act progress, Elevance Medicaid exits, plus the new Alignment tripwire